准分子激光角膜切削术治疗高度近视远期疗效分析

目的:评价准分子激光角膜切削术(photorefractive keratectomy, PRK)治疗高度近视的远期疗效.方法:将104例183眼屈光度>-6.00D患者分两组,Ⅰ组-6.25～-10.00D,Ⅱ组≥-10.25D,对PRK术后3年患者的视力、屈光度、角膜上皮下基质混浊进行随访分析.结果:3年时Ⅰ组裸眼视力达到术前最佳矫正视力的为73.3%(96眼),Ⅱ组为38.5%(20眼);屈光度在预期矫正度±1.00D以内者,Ⅰ组为76.3%(100眼),Ⅱ组为42.3%(22眼);角膜上皮下基质混浊,3年时0～0.5级的Ⅰ组为100%,Ⅱ组为90.4%.结论:PRK治疗-6.25～-10.00D的高度近视远期疗效较好,大于-10.00D的远期疗效不理想.     

PRK治疗近视术后远期疗效分析

目的:评价PRK治疗近视及散光的远期疗效。方法:选取1996-11/1998-01PRK手术116例(219眼),按术前等值球镜度分为3组,A组:-1.00D~-3.00D53眼;B组:-3.125D~-6.00D125眼;C组:-6.125D~-16.00D41眼。术后随访10a。结果:术后10a裸眼视力≥0.5、≥1.0者,A组分别为100%、84.9%;B组分别为100%、80.8%;C组分别为92.7%、31.7%。术后10a屈光度在预定矫正度±1.00D以内者,A、B、C组依次为92.5%,74.4%,34.2%。术后10a最佳矫正视力达到或超过术前最佳矫正视力者依次98.1%、98.4%、92.2%。无1例有1级以上角膜上皮下雾状浑浊(Haze)者。结论:PRK是治疗近视安全有效的方法,其预测性及稳定性与近视度呈负相关。     

准分子激光角膜原位磨镶术治疗近视术后眼压分析

目的探讨非接触性眼压计测量准分子激光角膜原位磨镶术(LASIK)治疗近视术后眼压变化及影响因素。方法选取-1.50-15.00D近视散光102例(198眼),每例按1眼参与分析,按预矫正等值球镜屈光度分为2组,Ⅰ组-1.50～6.00D56眼,Ⅱ组-6.25—15.0D42眼,用非接触眼压计测量术前及术后1月眼压,并分析术后眼压变化的因素。结果两组术后1月眼压均低于术前(P<0.05),术后随访1月以上显示高度组眼压降低幅度明显高于低中度组(P<0.05)。结论非接触性眼压计测量LASIK术后眼压值要进行修正,尤其在诊断青光眼或高眼压症时应慎重对待。     

准分子激光屈光性角膜切削术治疗近视、散光术后3年疗效分析

目的 为了评价准分子激光屈光性角膜切削术治疗近视、近视散光的远期疗效。方法 应用美国VISX 20/20型准分子激光仪,治疗132例(259眼),采用多切削区治疗屈光度-1.5D～-16.0D的近视观察3年以上,按术前球镜屈光度分为二组:Ⅰ组-1.5D～-6.0D(196眼),Ⅱ组-6.25D～-16.0D(73眼)。结果 术后3年裸眼视力≥0.5,在Ⅰ、Ⅱ中组中分别为94.6％、89.3％;术后3年裸眼视力≥1.0,在Ⅰ、Ⅱ组中分别为90.7％、70.5％,角膜HazeⅠ组0级90.3％,0.5级9.7％,无1级以上Haze;Ⅱ组0级63.0％,0.5级34.2％,1级2.8％,无2级以上Haze。结论 准分子激光屈光性角膜切削术对低、中、高度近视、近视散光均取得良好的远期效果,但对低、中度近视效果更佳,对高度近视预测性较差。     

準分子激光原位角膜磨鑲衍矯正近視449例

目的 探讨准分子激光原位角膜磨镶术(LASIK)治疗低、中、高度近视的疗效。方法 应用波长193nm的ArF准分子激光对449例(889眼)屈光度在-0.75D～21.00D的近视及近视散光行LASIK治疗。结果 对889跟随访12～24月,93％术后裸视达到或超过术前最好矫正视力,5.6％的裸视达2.0,90.3％的术后屈光度在±1.00D之间,欠矫67眼,欠矫率仅为7.5％,术中术后未见严重并发症。给论 LASIK手术矫正近视及近视散光优于PRK手术,是一种更加准确有效和安全的屈光手术方法。     

准分子激光原位角膜磨镶术治疗近视二年疗效分析

目的 探讨准分子激光原位角膜磨镶术(laser in situ keratomileusis,LASIK)治疗近视2年疗效.方法 对2007年3月至2009年4月在杭州师范大学附属医院眼科就诊的500例996只近视眼进行LASIK治疗,按术前预矫等效球镜屈光度分为3组,Ⅰ组:-1.50～-6.00 D,Ⅱ组:-6.10～-10.00 D,Ⅲ组:-10.10～-14.00 D,术后随访2年.结果 术后2年,Ⅰ组:裸眼视力≥0.5和≥1.0分别为100％和96.03％,术后屈光度±0.50 D、±1.00 D以内者分别占87.03％和94.98％,术后散光±1.00 D以内者占97.91％.Ⅱ组:裸眼视力≥0.5和≥1.0分别为100％和84.12％,术后屈光度±0.50 D、±1.00 D以内者分别占83.89％和91.00％,术后散光±1.00 D以内者占94.79％.Ⅲ组:裸眼视力≥0.5和≥1.0分别为89.58％和75.00％,术后屈光度±0.50 D、±1.00 D以内者分别占64.58％和76.04％,术后散光±1.00 D以内者占87.50％.结论 采用LASIK治疗近视具有良好安全性、有效性、可预测性和稳定性.     

准分子激光角膜切削术矫正RK术后近视22例

目的:探讨准分子激光角膜切削术(PRK)矫正角膜放射状切开术(RK)后残留近视及近视散光的有效性和安全性。方法:应用波长193nm的ArF准分子激光对22例39眼RK术后残留的近视及近视散光进行准分子激光屈光手术治疗。结果:随访5a,平均屈光度由术前-4.21±1.42D下降至术后的-0.41±0.31D,34眼≥术前最佳矫正视力,术前裸眼视力≥1.0者32眼,术后裸眼视力≥1.0者30眼,回退4眼(10%),回退度数<-1.25D。术前矫正视力≤0.9者,术后5a时仅2眼裸眼视力≥1.0。结论:PRK是一种有效和安全的矫正RK术后残留近视的方法。     

准分子激光角膜屈光手术治疗近视及近视散光的疗效观察

目的评价准分子激光角膜屈光手术治疗近视的疗效。方法采用准分子激光角膜切削仪和自动报层角膜刀对332例628只眼近视及散光患者行PRK或Lasik手术，术前球镜屈光度-1．00～－23．00D（-6．12±4．05D），柱镜屈光度0～－5．00D，角膜屈光力43．35±1．31，术后随访一年。结果术后1年裸眼视力≥0．8占90．76％，实际矫正屈光度与预测矫正度绝对值差在±1．50D范围内达91％，术后半年角膜屈光力38．14±2．63。结论该手术具有安全、准确、可预测性强、矫正近视范围大等优点，低中度近视可选PRK手术，高度近视尤为-8．00D以上者，应选择Lasik手术，强调长期观察的重要性。     

准分子激光屈光性角膜切削术治疗近视,近视散光2年结果分析

为了评价准分子激光屈光性角膜切削术治疗近视、近视散光的疗效。应用美国ＶＩＳＸ２０／２０型准分子激光仪,采用多削区治疗近视屈光度为－１．７５～－１６．００Ｄ的患者,观察２年以上,按术前球镜屈光度分为二组,Ⅰ组为－１．７５～６．００Ｄ（１２１眼）,Ⅱ组为－６．２５～－１６．００Ｄ（８６眼）。术后２年裸眼视力≥０．５者在Ⅰ、Ⅱ组中分别为９５．９％、７０．９％,≥１．０者分别为７３．６％、３４．９％。Ⅰ、Ⅱ组中屈光度在±１．００Ｄ以内者分别为９１．７％、６２．８％。角膜上皮下混浊０度在Ⅰ、Ⅱ组中分别为８７．６％、６６．３％,２级以上分别为０、１．２％。眼压均正常。结论：准分子激光屈光性角膜切削术对低、中、高度近视、近视散光均取得良好的远期效果,但对低、中度近视效果更佳,对高度近视预测性较差。     

准分子激光术治疗近视眼164例术后远期疗效观察

目的观察评价准分子激光角膜切削术(photorehaefive keratectomy，PRK)和准分子激光原位角膜磨镶术(excimer laser insitu keralcmileusis，LANK)治疗近视眼术后的远期疗效。方法对。164例328眼，按手术方法，近视屈光度分为两组，一组行PRK手术，屈光度-1．25DS～-7．00DS，二组行LASIK手术，屈光度-2．50DS～一12．00DS，对行准分子激光治疗后1～6年患者的视力、并发症角膜上皮下基质混浊、眼压进行观察分析。结果裸眼视力达到术前最佳矫正视力(≥5．0)，PRK组为75％(114眼)，LASIK组为78．4％(138眼)，角膜下基质混浊，影响视力，PRK组6％，LASIK组未见角膜混浊，眼压平均12mmHg。结论准分子激光治疗近视安全有效，大部分远期疗效较好，PRK组个别患者发生角膜混浊，应引起重视。     

准分子激光屈光性角膜切削术后屈光回退的多因素分析

目的：探讨准分子激光屈光性角膜切削术后屈光回退的主要因素。方法：采用VISX20／20型准分子激光仪对121例214眼近视患者行准分子激光角膜切削术,术后随访2年。分二组进行比较,Ⅰ组为低中度近视（－1．00D－－6．00D）124眼,Ⅱ组为高度近视（－6．25D－－16．00D）90眼。结果：术后2年低中度近视回退率9．7％,高度近视回退率27．8％（P＜0．005）,高度近视中高龄组较低龄组回退率高（P＜0．005）,较严重的角膜上皮下雾状混浊与回退伴行。结论：准分子激光角膜切削术后屈光回退的主要因素有预期矫正屈光度,角膜Haze及年龄。     

准分子激光屈光性角膜切削术后的再治疗

目的 评价准分子激光屈光性角膜切削术（ｐｈｏｔｏｒｅｆｒａｃｔｉｖｅ ｋｅｒａｔｅｃｔｏｍｙ,ＰＲＫ）术后因屈光回退,欠矫出现的残留近视及严重角膜上皮下雾状混沌（ｈａｚｅ）而再次手术治疗的疗效及安全性。方法 采用准分子激光仪对－１．００～－１６．５０Ｄ的近视眼及近视散光患者进行治疗。ＰＲＫ术后３５例（５１只眼）患者出现残留近视及严重ｈａｚｅ。结合ＰＲＫ手术及准分子激光治疗性角膜切削术（ｐｈｏｔｏｐ     

Analysis of refractive state after excimer laser photorefractive keratectomy in myopia]

OBJECTIVE: To evaluate refractive state after excimer laser photorefractive keratectomy (PRK) in patients with myopia. METHODS: 234 cases(391 eyes) followed up for two years were divided into two groups, group I: mild and moderate myopia(< or = -6.00 D), 228 eyes; group II: High myopia(> -6.00 D), 163 eyes. The refractive state of patients at three, six, twelve and twenty-four months postoperatively were monitored. RESULTS: At two years after photorefractive keratectomy (PRK), refractive regression (> -0.5 D), overcorrection(> 1.00 D), undercorrection(> 1.00 D), postoperative residual astigmatism postoperative astigmatism and hyperopia shift in group I were 1.7%, 4.4%, 5.7%, 12.8%, 7.4% and 7.5% respectively, while in high myopia group were 15.9%, 4.9%, 23.3%, 29.7%, 31.1% and 6.7% respectively. CONCLUSION: The results prove that photorefractive keratectomy is an effective, precise, stable and safe method for correction of mild and moderate myopia, but insufficient for high myopia.     

Eight-year follow-up of photorefractive keratectomy for myopia

PURPOSE: We evaluated 8-year results of excimer laser photorefractive keratectomy (PRK) for myopia in terms of stability and late complications. METHODS: Ninety-two myopic eyes of 55 patients were treated with a single-step method using an Aesculap-Meditec MEL 60 excimer laser with a 5.0-mm ablation zone. Treated eyes were divided into three groups according to preoperative refraction: low myopes (< or = -6.00 D), medium myopes (-6.10 to -10.00 D), and high myopes (>-10.00 D). RESULTS: Change in myopic regression stabilized in all myopia groups within 12 months, although a small myopic shift occurred up to 8 years after PRK. Mean change in refraction between 2 and 8 years was -0.42 +/- 0.48 D for low myopes, -0.37 +/- 0.34 D for medium myopes, and -0.41 +/- 0.50 D for high myopes. The percentage of eyes within +/- 1.00 D of emmetropia 8 years after PRK was 78.3% in the low myopia group, 68.8% in the medium myopia group, and 57.1% in the high myopia group. One eye lost 2 lines of best spectacle-corrected visual acuity due to irregular astigmatism. In 13.0% of eyes, a residual trace corneal haze was observed, which had no effect on visual acuity. Apart from the loss of 2 lines of BSCVA in one eye, there were no other late complications during the study period. CONCLUSIONS: The mean change in refraction between 2 and 8 years was less than -0.50 D, regardless of preoperative refraction, and may be attributed to natural age-related refractive change. The appearance of residual corneal haze after 8 years correlated with the amount of myopic correction. PRK was a safe and stable surgical procedure in this group of patients.     

Photorefractive keratectomy or laser in situ keratomileusis for residual refractive error after phakic intraocular lens implantation

PURPOSE: To evaluate the results of combining phakic posterior chamber intraocular lens (IOL) implantation and excimer corneal surgery to treat high myopia or myopia with astigmatism. SETTING: Service d'Ophtalmologie, H?pital Purpan, University of Toulouse, Toulouse, France. METHODS: Thirty-two eyes of 28 patients with extreme myopia or myopia combined with astigmatism were treated by implantation of a phakic posterior chamber IOL. Residual refractive errors were treated no earlier than 6 weeks after IOL implantation by photorefractive keratectomy (PRK) in eyes with low refractive errors or by laser in situ keratomileusis (LASIK) in eyes with higher residual refractive errors. RESULTS: The mean preoperative spherical equivalent (SE) refraction was -18.7 diopters (D). The refractive astigmatism ranged from 0 to 3.5 D. After excimer laser treatment, the SE refraction ranged from -0.5 to -2.5 D and the refractive astigmatism, from 0 to 1.5 D in the PRK group. In the LASIK group, spherical ametropia ranged from -1.5 to +1.5 D and astigmatism, from 0 to 1.0 D. After excimer laser treatment, the uncorrected visual acuity improved in all eyes but a loss of 1 line of the corrected vision after IOL implantation occurred in 22.2% of PRK-treated eyes and in 13.6% of LASIK-treated eyes. CONCLUSIONS: Bioptic treatment of extreme myopia and myopia associated with astigmatism appears to be safer and more predictable than other methods of treatment.     

Photorefractive keratectomy for myopia with the Meditec MEL 70G-Scan flying spot laser

PURPOSE: To evaluate the efficacy, predictability, stability, and safety of the Meditec MEL 70G-Scan flying spot excimer laser. METHODS: One hundred thirty myopic eyes were treated with the Aesculap Meditec Mel 70G-Scan ArF flying spot excimer laser with photorefractive keratectomy (PRK). Patient groups: low myopia (Group 1) from -1.50 to -6.00 D (90 eyes), medium myopia (Group 2) from -6.10 to -9.00 D (31 eyes), high myopia (Group 3) from -9.10 to -14.00 D (9 eyes). RESULTS: At 12 months in the low myopia group, uncorrected visual acuity (UCVA) of 20/40 or better was achieved in 95.5% (86 eyes), 20/20 or better in 77.7% (70 eyes); 2.2% (two eyes) lost two or more lines of best spectacle-corrected visual acuity (BSCVA); 73.3% (66 eyes) were within +/-0.50 D of the target correction and 98.8% (89 eyes) were within +/-1.00 D. In the medium myopia group, UCVA of 20/40 or better was achieved in 74.2% (23 eyes), 20/20 or better in 25.8% (eight eyes); 3.2% (one eye) lost two lines, 61% (19 eyes) were within +/-0.50 D of desired correction and 83.8% (26 eyes) were within +/-1.00 D. In the high myopia group, UCVA of 20/40 or better was achieved in 22.2% (two eyes); 20/25 or better in 11.1% (one eye); none of the eyes achieved 20/20 UCVA; 22.2% (two eyes) lost two lines of BSCVA; 44.4% (four eyes) were within +/-0.50 D and 66.6% (six eyes) were within +/-1.00 D of the target correction. Refractive stability was achieved between 3 and 6 months. Increased intraocular pressure was detected overall in 7.69%. CONCLUSIONS: The results of predictability, safety, and efficacy in low and medium myopia with the Meditec MEL 70G-Scan flying spot excimer laser were good, but poorer predictability, regression, and a significant loss of BSCVA were observed in the high myopia group.     

准分子激光原位角膜磨镶术治疗近视的并发症

目的 分析准分子原位角膜磨镶术（ｅｘｃｉｍｅｒ ｌａｓｅｒ ｉｎ ｓｉｔｕ ｋｅｒａｔｏｍｉｌｕｓｉｓ,ＬＡＳＩＫ）治疗近视的并发症,探讨其发生原因及预防措施。方法 ６６２例（１２６５只眼）近视患者（－２．００～２５．００Ｄ）按屈光度分为３组：Ａ组７２６只眼,≤－６．００Ｄ;Ｂ组２８７只眼,－６．２５～－１０．００Ｄ）;Ｃ组２５２只眼,〉－１０．００Ｄ;行ＬＡＳＩＫ后均随访１２个月,观察及分析其并     

Treatment of myopia and myopic astigmatism by customized laser in situ keratomileusis based on corneal topography

OBJECTIVE: To evaluate the predictability, efficacy, and safety of customized laser in situ keratomileusis (LASIK) based on corneal topography in myopia and myopic astigmatism. DESIGN: Prospective, noncomparative interventional case series. PARTICIPANTS: One hundred fourteen patients (eyes) with myopia of -1 to -6 diopters (D) and astigmatism of 0 to -4 D (low myopia group), and 89 patients (eyes) with myopia of -6.10 to -12.00 D and astigmatism of 0 to -4.00 D (high myopia group). INTERVENTION: LASIK was performed with the Hansatome Microkeratome and the Keracor 217 spot-scanning excimer laser (Bausch & Lomb Surgical Technolas, Munich, Germany). Individual ablation patterns were calculated on the basis of elevation data obtained with the Orbscan II corneal topography system (Bausch & Lomb Surgical, Irvine, CA). MAIN OUTCOME MEASURES: Manifest spectacle refraction, visual acuity, and change in visual acuity at 3 months after surgery. RESULTS: At 3 months, 51 patients in the low myopia group and 40 patients in the high myopia group were available. In the low (high) myopia group, 96.1% (75.0%) were within +/-0.50 D of emmetropia, and uncorrected visual acuity was 20/20 or better in 82.4% (62.5%), 20/25 or better in 98.0% (70.0%), and 20/40 or better in 100% (95.0%). A loss of two or more lines of spectacle-corrected visual acuity occurred in 3.9% of the low and 5. 0% of the high myopia group. In low myopia, spectacle-corrected visual acuity was 20/12.5 or better in 5.9% preoperatively and in 13.7% at 3 months and 20/15 or better in 37.3% and 47.1%, respectively. Differences were statistically significant. CONCLUSIONS: The customized LASIK based on corneal topography used in this study showed high predictability and efficacy in myopia and myopic astigmatism of -1.00 to -6.00 D, and could possibly improve spectacle-corrected visual acuity in myopia of -1.00 to -6.00 D. Predictability and efficacy were somewhat lower in myopia and myopic astigmatism of -6.10 to -12.00 D. In both groups, a small number of patients lost two or more lines of spectacle-corrected visual acuity.     

Photorefractive keratectomy for residual myopia after cataract surgery

PURPOSE: To evaluate the effectiveness, predictability, and safety of photorefractive keratectomy (PRK) for correcting residual myopia and myopic astigmatism after cataract surgery with intraocular lens implantation. SETTING: Refractive Surgery and Cornea Unit, Instituto Oftalmológico de Alicante, Alicante, Spain. METHODS: Thirty consecutive eyes (30 patients) had PRK for residual myopia after cataract surgery. Surface PRK with a VISX Twenty-Twenty excimer laser was used in all patients. Follow-up was 1 year. RESULTS: Before PRK, no eye had an uncorrected visual acuity (UCVA) of 20/40 or better. Twelve months after PRK, 16 eyes (53.33%) had a UCVA of 20/40 or better. After PRK, best corrected visual acuity (BCVA) improved 1 line or more in 14 eyes (46.66%) over the preoperative values, and 15 eyes (50.00%) had the same BCVA as before PRK. Mean pre-PRK refraction of -5.00 diopters (D) +/- 2.50 (SD) decreased significantly to -0.25 +/- 0.50 D at 12 months (P < .001). At 12 months, the spherical equivalent was within +/- 1.00 D of emmetropia in 27 eyes (90.00%). No vision-threatening complications occurred. CONCLUSION: Photorefractive keratectomy was an effective, predictable, and safe procedure for correcting residual myopia and myopic astigmatism after cataract surgery.